Similarly, the model predicts greater sensitivity (lower IC50) to isocitrate dehydrogenase (IDH) inhibitors in patients with mutant IDH (mIDH) gliomas compared to wild-type IDH (wtIDH) cases (Figure 1(BII)). This evidence concerns the gene IDH3A and glioma.